Oren Gilad

Doylestown Hospital — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index2.3kcitations43works0.42yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(17), Aquaculture disease management and microbiota(9), Cancer-related Molecular Pathways(8), Cell death mechanisms and regulation(7), Animal Virus Infections Studies(6)

Publications43 total

Abstract 2907: A first-in-class series of potent and selective macrocyclic ATR inhibitors
Cancer Research·2025
336 (PB324): Development and testing of a first-in-class series of macrocyclic ATR inhibitors for cancer treatment
European Journal of Cancer·2024
335 (PB323): The novel WEE1i, APR-1051, does not substantially off-target PLK1, PLK2, or PLK3 and exhibits favorable in vivo characteristics for treating CCNE1-overexpressing cancers
European Journal of Cancer·2024
Abstract 7121: The novel WEE1i, APR-1051, is a potentially well tolerated and effective treatment for cyclin E-overexpressing cancers
Cancer Research·2024· 2 cited
Abstract 7117: Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma
Cancer Research·2024
Abstract C147: The DNA replication checkpoint inhibitors, ATRN-1051 (WEE1i) and ATRN-119 (ATRi), are potentially well tolerated and effective cancer treatments
Molecular Cancer Therapeutics·2023· 1 cited
Abstract 6177: ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment
Cancer Research·2023· 2 cited
Data from Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
2023Open Access
Supplementary Data from Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
2023Open Access
Data from Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
2023Open Access
Supplementary Data from Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
2023Open Access
Data from Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
2023Open Access
Supplementary Figures 1-5 from Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
2023Open Access
Supplementary Figures 1-5 from Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
2023Open Access
Supplementary Table 1 from Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
2023Open Access
Data from Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
2023Open Access
Supplementary Table 1 from Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner
2023Open Access
Synthetic-lethal interactions between ATR inhibition and functional genetic and proteomic biomarkers to predict responses in endometriosis-associated cancers.
Journal of Clinical Oncology·2020· 2 cited
Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors
Cancer Research·2019· 92 citedOpen Access
Abstract 3498: Highly specific macrocyclic ATR inhibitors for the targeted treatment of a broad spectrum of cancers showing lack of anemia or neutropenia in pre-clinical animal models
Cancer Research·2019
page 1 of 3Next →

Frequent Co-authors

Eric J. Brown(22), Ryan L. Ragland(13), Fiona Simpkins(11), Erin George(9), Barzin Y. Nabet(8), David W. Schoppy(8), Amy C. Durham(8), Hank Breslin(8), Laura Butler(7), Ronald P. Hedrick(6), Ranjini K. Sundaram(6), Ranjit S. Bindra(6), Molly M. Hansbarger(6), Lanqi Jia(6), Hervé Bercovier(5), Christopher Jackson(5), Seth Noorbakhsh(5), Aravind Kalathil(5), Sachita Ganesa(5), Danielle M. Burgenske(5)